Evidence map›Paper›PMID 35871348›Full record

ArticleJournal of Alzheimer's disease : JAD2022

Costs of Persons with Dementia Living in Nursing Homes in The Netherlands.

Philip Charles Gerard Klein, Simone Huygens, Ron Handels, Valérie Wester, Tim Andre Kanters

Open access · hybridAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Philip Charles Gerard KleinInstitute for Medical Technology Assessment, Erasmus University of Rotterdam, Erasmus School of Health, Policy & Management, Rotterdam, The Netherlands.
Simone HuygensInstitute for Medical Technology Assessment, Erasmus University of Rotterdam, Erasmus School of Health, Policy & Management, Rotterdam, The Netherlands.
Ron HandelsAlzheimer Centre Limburg, Maastricht University Medical Centre+; Faculty of Health, Medicine and Life Sciences; School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Maastricht, The Netherlands.
Valérie WesterInstitute for Medical Technology Assessment, Erasmus University of Rotterdam, Erasmus School of Health, Policy & Management, Rotterdam, The Netherlands.
Tim Andre KantersInstitute for Medical Technology Assessment, Erasmus University of Rotterdam, Erasmus School of Health, Policy & Management, Rotterdam, The Netherlands.
Erasmus University Rotterdam · NLMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisease modifying treatments (DMTs) currently under development for Alzheimer's disease, have the potential to prevent or postpone institutionalization and more expensive care and might delay institutionalization of persons with dementia.

objectiveThe current study estimates costs of living in a nursing home for persons with dementia in the Netherlands to help inform economic evaluations of future DMTs.

methodsData were collected during semi-structured interviews with healthcare professionals and from the financial administration of a healthcare organization with several nursing homes. Personnel costs were calculated using a bottom-up approach by valuing the time estimates. Non-personnel costs were calculated using information from the financial administration of the healthcare organization.

resultsTotal costs of a person with dementia per 24 hours, including both care staff and other healthcare providers, were € 151 for small-scale living wards and € 147 for independent living wards. Non-personnel costs were € 37 per day.

conclusionThis study provides Dutch estimates for total healthcare costs per day for institutionalized persons with dementia. These cost estimates can be used in cost-effectiveness analyses for future DMTs in dementia.

Indexed as

DementiaHealth Care CostsHumansInstitutionalizationNetherlandsNursing HomesDementiahealth care economics and organizationshealth resourcesnursing homes

Identifiers

PMID35871348
PMCPMC9535598
OpenAlexW4286562716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.